Boothwyn Pharmacy recalls 642 vials of semaglutide 2.5 mg/mL injection sold nationwide in the U.S. The recall cites subpotent drug with Class II designation. Consumers and healthcare providers should stop using the product immediately and contact Boothwyn Pharmacy for guidance.
Subpotent Drug
Consumers and healthcare providers should stop using this product immediately. Contact Boothwyn Pharmacy LLC or your healthcare provider for guidance. Notification method: Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
Semaglutide injections are used to improve glycemic control in type 2 diabetes and for weight management in obesity. They are prescribed and distributed through pharmacies.
Subpotent drugs may provide insufficient therapeutic effect, risking poor disease management and complications.
This recall is not part of a broader industry pattern in the provided data.
Patients may require medical adjustment or replacement therapy to maintain therapeutic outcomes.
FDA enforcement page or Boothwyn Pharmacy recall notices.
Refunds/replacements are determined by Boothwyn Pharmacy and may take weeks.
Keep recall notices, lot/model numbers, purchase records, and correspondence with pharmacy and providers.
Brand: Boothwyn Pharmacy. Product: Semaglutide, 2.5 mg/mL injection, 2 mL. Quantity: 642 vials. Distribution: U.S. Nationwide. Recall Date: 2025-07-09. Status: ACTIVE. Models: 03202025@5, 03202025@6, 03202025@7, 03202025@8 BUD 07/18/2025.
No injuries or incidents have been reported.
Not sure what to do next? Our guide walks you through the process step by step.
Read: What to Do When You Find a Recalled ProductGet instant alerts for recalls that affect you. Free forever.
Boothwyn Pharmacy LLC issued a nationwide recall of 186 vials of Semaglutide 2.5 mg/mL injection, 0.8 mL, on July 9, 2025. The FDA enforcement report classifies the recall as Class II with a high hazard level. Consumers and healthcare providers should stop using the product immediately and follow guidance from Boothwyn Pharmacy or a healthcare provider.
Boothwyn Pharmacy recalls 8 vials of Fluorescein 2% Ophth 3 mL nationwide after a subpotent drug finding. The recall was issued July 9, 2025 and remains active.
Boothwyn Pharmacy recalls 648 vials of semaglutide 2.5 mg/mL injection nationwide after detecting subpotent potency. The recall involves products distributed across the U.S. and is classified as Class II with a high hazard level. Stop using the product and contact Boothwyn Pharmacy or a healthcare provider for guidance.